Find information on thousands of medical conditions and prescription drugs.

Basiliximab

Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody to the IL-2Rα receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis Pharmaceuticals product and was approved by the FDA in 1998. more...

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It is given in two doses, the first within 2 hours of the start of the transplant operation and the second 4 days after the transplant. These saturate the receptors and prevent T cell activation and thus prevent formation of antibodies against the transplant.

Like the similar drug daclizumab, basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections. In the United Kingdom, the National Institute for Clinical Excellence has recommended its use be considered for all kidney transplant recipients.

References & Notes

  1. ^  IL-2Rα receptor is also known as the CD25 T-cell antigen
  2. ^  Novartis product page for Simulect (basiliximab for injection) . Retrieved 2005-03-09.
  3. ^  Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277.

Read more at Wikipedia.org


[List your site here Free!]


Basiliximab (Simulect[R]): Simplifying Induction Therapy. : An article from: Nephrology Nursing Journal $5.95

Preliminary Data Regarding The Use Of Interleukin-2 Receptor Antibodies In Lung Transplantation - Daclizumab & Basiliximab - Abstract
Purpose: Daclizumab and Basiliximab have been demonstrated to decrease the frequency of acute rejection(AR) in the first 6 months after renal transplantation ...
Iron accumulation in lung allografts is associated with acute rejection but not with adverse outcome
Background: Iron content in lung allografts is increased after transplantation. It was hypothesized that this may lead to fibrosis and posttransplant ...
Molecular evidence of Pneumocystis transmission in pediatric transplant unit
We describe an outbreak of Pneumocystis jirovecii pneumonia in a pediatric renal transplant unit, likely attributable to patient-to-patient transmission.
Atrial fibrillation after pulmonary transplant
Background: Although atrial fibrillation or flutter (AF) is thought to occur commonly after pulmonary transplantation, little is known about the epidemiology, ...
Respiratory Viral Infections Are a Distinct Risk for Bronchiolitis Obliterans Syndrome and Death
Bronchiolitis obliterans syndrome (BOS) is the major obstacle to long-term survival after lung transplantation, in part because its pathogenesis is poorly ...
Future immunosuppressive agents in solid-organ transplantation
Objective-To review the pharmacology, pharmacokinetics, efficacy, and safety of mycophenolate sodium, everolimus, and FTY720. Study Selection and Data ...
Posttransplant lymphoproliferative disorder : incidence, presentation, and response to treatment in lung transplant recipients - clinical investigations
Introduction: Posttransplant lymphoproliferative disorder (PTLD) is a relatively infrequent but devastating complication that occurs after solid-organ ...
Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients? - clinical investigations
Study objectives: Lung transplantation continues to be limited by the development of chronic allograft dysfunction in the form of bronchiolitis obliterans ...

Home Contact Resources Exchange Links ebay